Cargando…

Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans

This study investigated the effects of ponesimod, a selective S1P(1) receptor modulator, on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and absolute numbers were determined at baseline and on Day 10, after once-daily administration of ponesimod (10 mg, 20 mg, and 40 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurcevic, Stipo, Juif, Pierre-Eric, Hamid, Colleen, Greenlaw, Roseanna, D’Ambrosio, Daniele, Dingemanse, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207338/ https://www.ncbi.nlm.nih.gov/pubmed/28096659 http://dx.doi.org/10.2147/DDDT.S120399

Ejemplares similares

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

FRA2 Is a STAT5 Target Gene Regulated by IL-2 in Human CD4 T Cells
por: Rani, Aradhana, et al.
Publicado: (2014)

Cardiodynamic Interactions between Two S1P(1) Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
por: Juif, Pierre-Eric, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan
por: Juif, Pierre‐Eric, et al.
Publicado: (2019)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes
por: You, Sylvaine, et al.
Publicado: (2013)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P(1)‐selective modulation
por: Kihara, Yasuyuki, et al.
Publicado: (2022)

Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
por: Coffey, Greg, et al.
Publicado: (2016)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice
por: Zhu, Zhihui, et al.
Publicado: (2023)

The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells
por: Safaeinejad, Fahimeh, et al.
Publicado: (2021)

T-Lymphocyte Subsets in Apparently Healthy Nigerian Children
por: Idigbe, Emmanuel Oni, et al.
Publicado: (2010)

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
por: Valenzuela, Belén, et al.
Publicado: (2022)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies
por: Freedman, Mark S., et al.
Publicado: (2022)

Molecular Analysis of Precursor Lesions in Familial Pancreatic Cancer
por: Crnogorac-Jurcevic, Tatjana, et al.
Publicado: (2013)

Discovering lymphocyte subsets
por: Van Epps, Heather L.
Publicado: (2005)

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
por: Mortoglou, Maria, et al.
Publicado: (2022)

Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa
por: Mandala, Wilson L., et al.
Publicado: (2010)

Reference Values for Peripheral Blood Lymphocyte Subsets in a Healthy Korean Population
por: Choi, Joungbum, et al.
Publicado: (2014)

Immune-Ageing Evaluation of Peripheral T and NK Lymphocyte Subsets in Chinese Healthy Adults
por: Jia, Zhenghu, et al.
Publicado: (2023)

Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults
por: Qin, Ling, et al.
Publicado: (2016)

Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic STAT1/STAT5 Signalling Response in Helper T Lymphocytes
por: Holcar, Marija, et al.
Publicado: (2015)

Reference ranges of T lymphocyte subsets by single-platform among healthy population in southwest China
por: Wei, Bin, et al.
Publicado: (2021)

Regulatory T-lymphocyte subsets in children with chronic immune thrombocytopenia after high-dose of dexamethasone
por: Elsayh, Khalid Ibrahim, et al.
Publicado: (2022)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset
por: Nörenberg, Jasper, et al.
Publicado: (2021)

Establishment of the reference intervals of lymphocyte subsets for healthy Chinese Han adults and its influencing factors
por: Xu, Kangli, et al.
Publicado: (2021)

Cumulative physiological stress is associated with age-related changes to peripheral T lymphocyte subsets in healthy humans
por: Snodgrass, Ryan G., et al.
Publicado: (2023)

Lymphocyte Subsets in Mild COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Rationale for targeting complement in COVID‐19
por: Polycarpou, Anastasia, et al.
Publicado: (2020)

Corrigendum: Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset
por: Nörenberg, Jasper, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38bfmqa1vkfggjagftng5pdh3k